No Picture
Trading Ideas

The federal government needs to take a role in ‘encouraging, counseling, advising governors about how they can serve the national interest’: Harvard Professor

President Trump claims he has ‘total’ authority to reopen the economy, but state governors say otherwise. Professor at Harvard Law School Mark Tushnet joins Yahoo Finance’s On The Move to break down who has the power to reopen the economy. …read more […]

No Picture
Business News

U.S. retail sales, factory output sink as economy reels from coronavirus

U.S. retail sales suffered a record drop in March and output at factories declined by the most since 1946, buttressing analysts’ views that the economy contracted in the first quarter at its sharpest pace in decades as extraordinary measures to control the spread of the novel coronavirus shut down the country.

…read more […]

No Picture
Business News

U.S. probe unable to rule out White House influence on JEDI contract awarded to Microsoft, not Amazon

The Pentagon’s inspector general on Wednesday said it could not determine whether the White House influenced the award of a $10 billion contract to Microsoft Corp over Amazon after several officials said their conversations were privileged “presidential communications.”

…read more […]

No Picture
Trading Ideas

3 “Strong Buy” Dividend Stocks Yielding At Least 9%

In last week’s trading, stocks showed their best weekly gains in over 40 years, prompting a wave of confidence among investors. But it’s not clear that the bulls really want to start running – today, the S&P slipped 2.5%. Volatility indicators remain high, as daily trading results remain unpredictable.The market gyrations are the direct result of the strong reactions to the COVID-19 epidemic. New York City, the world’s financial center, is clearly at the center of the epidemic in the US, but social distancing, shutdowns, lockdowns, and quarantines are being applied in varying degrees throughout the country – and worldwide. …read more […]

Uncategorized

CytoDyn’s (OTC: CYDY) Phase 2 Basket Trial for 22 Solid Cancer Tumors Treats First Patient with Leronlimab; Patient Enrollment Delayed Due to COVID-19

VANCOUVER, Washington, April 15, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has […]